Obesity and drug pharmacology: a review of the influence of obesity on pharmacokinetic and pharmacodynamic parameters

References

• Flegal KM, Carroll MD, Kuczmarski RJ, et al. Overweight and obesity in the United States: prevalence and trends, 1960-1994. Int J Obes Relat Metab Disord. 1998;22:39–47.
   PubMed Web of Science ®Google Scholar
• GBD 2015 Obesity Collaborators. Health effects of overweight and obesity in 195 countries over 25 years. N Engl J Med. 2017;377:13–27.
   PubMed Web of Science ®Google Scholar
• Flegal KM, Kruszon-Moran D, Carroll MD, et al. Trends in obesity among adults in the United States, 2005 to 2014. Jama. 2016;315:2284–2291.
   PubMed Web of Science ®Google Scholar
• Jensen MD, Ryan DH, Apovian CM, et al. 2013 AHA/ACC/TOS Guideline for the management of overweight and obesity in adults. J Am Coll Cardiol. 2014;63:2985–3023.
   PubMed Web of Science ®Google Scholar
• Jain R, Chung SM, Jain L, et al. Implications of obesity for drug therapy: limitations and challenges. Clin Pharmacol Ther. 2011;90:77–89.
   PubMed Web of Science ®Google Scholar
• Knibbe CAJ, Brill MJE, Van Rongen A, et al. Drug disposition in obesity: toward evidence-based dosing. Annu Rev Pharmacol Toxicol. 2015;55:149–167.
   PubMed Web of Science ®Google Scholar
• Brill MJE, Diepstraten J, Van Rongen A, et al. Impact of obesity on drug metabolism and elimination in adults and children. Clin Pharmacokinet. 2012;51:277–304.
   PubMed Web of Science ®Google Scholar
• Hanley MJ, Abernethy DR, Greenblatt DJ. Effect of obesity on the pharmacokinetics of drugs in humans. Clin Pharmacokinet. 2010;49:71–87.
   PubMed Web of Science ®Google Scholar
• Krekels EHJ, Van Hasselt JGC, Van Den Anker JN, et al. Evidence-based drug treatment for special patient populations through model-based approaches. Eur J Pharm Sci. 2017;109S:S22–S26.
   PubMedGoogle Scholar
• Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults–The evidence report. National Institutes of Health. Obes Res. 1998;6(Suppl 2):51S–209S.
   PubMedGoogle Scholar
• Wellen KE, Hotamisligil GS. Obesity-induced inflammatory changes in adipose tissue. J Clin Invest. 2003;112:1785–1788.
   PubMed Web of Science ®Google Scholar
• Cardoso-Júnior A, Coelho LGV, Savassi-Rocha PR, et al. Gastric emptying of solids and semi-solids in morbidly obese and non-obese subjects: an assessment using the 13C-octanoic acid and 13C-acetic acid breath tests. Obes Surg. 2007;17:236–241.
   PubMed Web of Science ®Google Scholar
• Teixeira TFS, Souza NCS, Chiarello PG, et al. Intestinal permeability parameters in obese patients are correlated with metabolic syndrome risk factors. Clin Nutr. 2012;31:735–740.
   PubMed Web of Science ®Google Scholar
• Xing J, Chen JDZ. Alterations of gastrointestinal motility in obesity. Obes Res. 2004;12:1723–1732.
   PubMedGoogle Scholar
• Alexander JK, Dennis EW, Smith WG, et al. Blood volume, cardiac output, and distribution of systemic blood flow in extreme obesity. Cardiovasc Res Cent Bull. 1962;1:39–44.
   PubMedGoogle Scholar
• Lemmens HJM, Bernstein DP, Brodsky JB. Estimating blood volume in obese and morbidly obese patients. Obes Surg. 2006;16:773–776.
   PubMed Web of Science ®Google Scholar
• Herrera MF, Deitel M. Cardiac function in massively obese patients and the effect of weight loss. Can J Surg. 1991;34:431–434.
   PubMed Web of Science ®Google Scholar
• Ong JP, Elariny H, Collantes R, et al. Predictors of nonalcoholic steatohepatitis and advanced fibrosis in morbidly obese patients. Obes Surg. 2005;15:310–315.
   PubMed Web of Science ®Google Scholar
• Farrell GC, Teoh NC, Mccuskey RS. Hepatic microcirculation in fatty liver disease. Anat Rec Adv Integr Anat Evol Biol. 2008;291:684–692.
   Web of Science ®Google Scholar
• Benedek IH, Fiske WD, Griffen WO, et al. Serum alpha 1-acid glycoprotein and the binding of drugs in obesity. Br J Clin Pharmacol. 1983;16:751–754.
   PubMed Web of Science ®Google Scholar
• Cheymol G, Poirier JM, Barre J, et al. Comparative pharmacokinetics of intravenous propranolol in obese and normal volunteers. J Clin Pharmacol. 1987;27:874–879.
   PubMed Web of Science ®Google Scholar
• Jones RL, Nzekwu -M-MU. The effects of body mass index on lung volumes. Chest. 2006;130:827–833.
   PubMed Web of Science ®Google Scholar
• Rubinstein I, Zamel N, DuBarry L, et al. Airflow limitation in morbidly obese, nonsmoking men. Ann Intern Med. 1990;112:828–832.
   PubMed Web of Science ®Google Scholar
• Davis G, Patel JA, Gagne DJ. Pulmonary considerations in obesity and the bariatric surgical patient. Med Clin North Am. 2007;91:433–442.
   PubMed Web of Science ®Google Scholar
• Ribstein J, Du Cailar G, Mimran A. Combined renal effects of overweight and hypertension. Hypertens (Dallas, Tex 1979). 1995;26:610–615.
   PubMed Web of Science ®Google Scholar
• Kasiske BL, Crosson JT. Renal disease in patients with massive obesity. Arch Intern Med. 1986;146:1105–1109.
   PubMed Web of Science ®Google Scholar
• Kovesdy CP, Furth S, Zoccali C, et al. Obesity and kidney disease: hidden consequences of the epidemic. Physiol Int. 2017;104:1–14.
   PubMed Web of Science ®Google Scholar
• Janmahasatian S, Duffull SB, Chagnac A, et al. Lean body mass normalizes the effect of obesity on renal function. Br J Clin Pharmacol. 2008;65:964–965.
   PubMed Web of Science ®Google Scholar
• Janmahasatian S, Duffull SB, Ash S, et al. Quantification of lean bodyweight. Clin Pharmacokinet. 2005;44:1051–1065.
   PubMed Web of Science ®Google Scholar
• Han PY, Duffull SB, Kirkpatrick CMJ, et al. Dosing in obesity: a simple solution to a big problem. Clin Pharmacol Ther. 2007;82:505–508.
   PubMed Web of Science ®Google Scholar
• Meyhoff CS, Lund J, Jenstrup MT, et al. Should dosing of rocuronium in obese patients be based on ideal or corrected body weight? Anesth. Analg. 2009;109:787–792.
   Google Scholar
• Schwartz SN, Pazin GJ, Lyon JA, et al. A controlled investigation of the pharmacokinetics of gentamicin and tobramycin in obese subjects. J Infect Dis. 1978;138:499–505.
   PubMed Web of Science ®Google Scholar
• Van Kralingen S, Van De Garde EMW, Knibbe CAJ, et al. Comparative evaluation of atracurium dosed on ideal body weight vs. total body weight in morbidly obese patients. Br J Clin Pharmacol. 2011;71:34–40.
   PubMed Web of Science ®Google Scholar
• Eleveld DJ, Proost JH, Absalom AR, et al. Obesity and allometric scaling of pharmacokinetics. Clin Pharmacokinet. 2011;50:751–756.
   PubMed Web of Science ®Google Scholar
• Griggs JJ, Mangu PB, Anderson H, et al. Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2012;30:1553–1561.
   PubMed Web of Science ®Google Scholar
• Green B, Duffull SB. What is the best size descriptor to use for pharmacokinetic studies in the obese?. Br J Clin Pharmacol. 2004;58:119–133.
   PubMed Web of Science ®Google Scholar
• Keys A, Fidanza F, Karvonen MJ, et al. Indices of relative weight and obesity. J Chronic Dis. 1972;25:329–343.
   PubMedGoogle Scholar
• Du Bois D, Du Bois EF. A formula to estimate the approximate surface area if height and weight be known. Arch Intern Med. 1916;XVII:863–871.
   Google Scholar
• McCarron M, Devine B. Gentamicin therapy. Drug Intell Clin Pharm. 1974;8:650–655.
   Google Scholar
• Ulvestad M, Skottheim IB, Jakobsen GS, et al. Impact of OATP1B1, MDR1, and CYP3A4 expression in liver and intestine on interpatient pharmacokinetic variability of atorvastatin in obese subjects. Clin Pharmacol Ther. 2013;93:275–282.
   PubMed Web of Science ®Google Scholar
• Flechner SM, Kolbeinsson ME, Tam J, et al. The impact of body weight on cyclosporine pharmacokinetics in renal transplant recipients. Transplantation. 1989;47:806–810.
   PubMed Web of Science ®Google Scholar
• Cheymol G, Weissenburger J, Poirier JM, et al. The pharmacokinetics of dexfenfluramine in obese and non-obese subjects. Br J Clin Pharmacol. 1995;39:684–687.
   PubMed Web of Science ®Google Scholar
• Greenblatt DJ, Abernethy DR, Locniskar A, et al. Effect of age, gender, and obesity on midazolam kinetics. Anesthesiology. 1984;61:27–35.
   PubMed Web of Science ®Google Scholar
• Bowman SL, Hudson SA, Simpson G, et al. A comparison of the pharmacokinetics of propranolol in obese and normal volunteers. Br J Clin Pharmacol. 1986;21:529–532.
   PubMed Web of Science ®Google Scholar
• Greenblatt DJ, Friedman H, Burstein ES, et al. Trazodone kinetics: effect of age, gender, and obesity. Clin Pharmacol Ther. 1987;42:193–200.
   PubMed Web of Science ®Google Scholar
• Kees MG, Weber S, Kees F, et al. Pharmacokinetics of moxifloxacin in plasma and tissue of morbidly obese patients. J Antimicrob Chemother. 2011;66:2330–2335.
   PubMed Web of Science ®Google Scholar
• Karlsson MO, Bredberg U. Estimation of bioavailability on a single occasion after semisimultaneous drug administration. Pharm Res. 1989;6:817–821.
   PubMed Web of Science ®Google Scholar
• Bredberg U, Karlsson MO, Borgström L. A comparison between the semisimultaneous and the stable isotope techniques for bioavailability estimation of terbutaline in humans. Clin Pharmacol Ther. 1992;52:239–248.
   PubMed Web of Science ®Google Scholar
• Brill MJE, Van Rongen A, Houwink API, et al. Midazolam pharmacokinetics in morbidly obese patients following semi-simultaneous oral and intravenous administration: A comparison with healthy volunteers. Clin Pharmacokinet. 2014;53:931–941.
   PubMed Web of Science ®Google Scholar
• Lee WH, Kramer WG, Granville GE. The effect of obesity on acetaminophen pharmacokinetics in man. J Clin Pharmacol. 1981;21:284–287.
   PubMed Web of Science ®Google Scholar
• Michalaki MA, Gkotsina MI, Mamali I, et al. Impaired pharmacokinetics of levothyroxine in severely obese volunteers. Thyroid. 2011;21:477–481.
   PubMed Web of Science ®Google Scholar
• Lloret-Linares C, Hirt D, Bardin C, et al. Effect of a Roux-en-Y gastric bypass on the pharmacokinetics of oral morphine using a population approach. Clin Pharmacokinet. 2014;53:919–930.
   PubMed Web of Science ®Google Scholar
• Hoskin PJ, Hanks GW, Aherne GW, et al. The bioavailability and pharmacokinetics of morphine after intravenous, oral and buccal administration in healthy volunteers. Br J Clin Pharmacol. 1989;27:499–505.
   PubMed Web of Science ®Google Scholar
• Van Rongen A, Välitalo PAJ, Peeters MYM, et al. Morbidly obese patients exhibit increased CYP2E1-mediated oxidation of acetaminophen. Clin Pharmacokinet. 2016.
   Web of Science ®Google Scholar
• Sanderink G-J, Le Liboux A, Jariwala N, et al. The pharmacokinetics and pharmacodynamics of enoxaparin in obese volunteers. Clin Pharmacol Ther. 2002;72:308–318.
   PubMed Web of Science ®Google Scholar
• Chan CCW, Ng EHY, Chan MMY, et al. Bioavailability of hCG after intramuscular or subcutaneous injection in obese and non-obese women. Hum Reprod. 2003;18:2294–2297.
   PubMed Web of Science ®Google Scholar
• Diepstraten J, Janssen EJH, Hackeng CM, et al. Population pharmacodynamic model for low molecular weight heparin nadroparin in morbidly obese and non-obese patients using anti-Xa levels as endpoint. Eur J Clin Pharmacol. 2015;71:25–34.
   PubMed Web of Science ®Google Scholar
• Rassard PAB, Gagnon-Auger M, Du Souich P, et al. Dose-dependent delay of the hypoglycemic effect of short-acting insulin analogs in obese subjects with a pharmacokinetic and pharmacodynamic study. Diabetes Care. 2010;33:0–5.
   Web of Science ®Google Scholar
• Berezhkovskiy LM. On the accuracy of estimation of basic pharmacokinetic parameters by the traditional noncompartmental equations and the prediction of the steady-state volume of distribution in obese patients based upon data derived from normal subjects. J Pharm Sci. 2011;100:2482–2497.
   PubMed Web of Science ®Google Scholar
• Hinderling PH. Red blood cells: a neglected compartment in pharmacokinetics and pharmacodynamics. Pharmacol Rev. 1997;49:279–295.
   PubMed Web of Science ®Google Scholar
• Abernethy DR, Greenblatt DJ, Divoll M, et al. Prolonged accumulation of diazepam in obesity. J Clin Pharmacol. 1983;23:369–376.
   PubMed Web of Science ®Google Scholar
• Davis RL, Quenzer RW, Bozigian HP, et al. Pharmacokinetics of ranitidine in morbidly obese women. Dicp. 1990;24:1040–1043.
   PubMedGoogle Scholar
• Van Kralingen S, Diepstraten J, Peeters MYM, et al. Population pharmacokinetics and pharmacodynamics of propofol in morbidly obese patients. Clin Pharmacokinet. 2011;50:739–750.
   PubMed Web of Science ®Google Scholar
• Abernethy DR, Greenblatt DJ, Smith TW. Digoxin disposition in obesity: clinical pharmacokinetic investigation. Am Heart J. 1981;102:740–744.
   PubMed Web of Science ®Google Scholar
• Adane ED, Herald M, Koura F. Pharmacokinetics of vancomycin in extremely obese patients with suspected or confirmed Staphylococcus aureus infections. Pharmacotherapy. 2015;35:127–139.
   PubMed Web of Science ®Google Scholar
• Blouin RA, Bauer LA, Miller DD, et al. Vancomycin pharmacokinetics in normal and morbidly obese subjects. Antimicrob Agents Chemother. 1982;21:575–580.
   PubMed Web of Science ®Google Scholar
• Abernethy DR, Greenblatt DJ, Divoll M, et al. The influence of obesity on the pharmacokinetics of oral alprazolam and triazolam. Clin Pharmacokinet. 2017;9:177–183.
   Google Scholar
• Brill MJE, Houwink API, Schmidt S, et al. Reduced subcutaneous tissue distribution of cefazolin in morbidly obese versus non-obese patients determined using clinical microdialysis. J Antimicrob Chemother. 2014;69:715–723.
   PubMed Web of Science ®Google Scholar
• Pai MP, Norenberg JP, Anderson T, et al. Influence of morbid obesity on the single-dose pharmacokinetics of daptomycin. Antimicrob Agents Chemother. 2007;51:2741–2747.
   PubMed Web of Science ®Google Scholar
• Abernethy DR, Greenblatt DJ, Divoll M, et al. Enhanced glucuronide conjugation of drugs in obesity: studies of lorazepam, oxazepam, and acetaminophen. J Lab Clin Med. 1983;101:873–880.
   PubMed Web of Science ®Google Scholar
• Smith MJ, Gonzalez D, Goldman JL, et al. Pharmacokinetics of clindamycin in obese and nonobese children. Antimicrob Agents Chemother. 2017;61:1–12.
   Web of Science ®Google Scholar
• Brunner M, Derendorf H, Müller M. Microdialysis for in vivo pharmacokinetic/pharmacodynamic characterization of anti-infective drugs. Curr Opin Pharmacol. 2005;5:495–499.
   PubMed Web of Science ®Google Scholar
• Rodvold KA, George JM, Yoo L. Penetration of anti-infective agents into pulmonary epithelial lining fluid: focus on antibacterial agents. Clin Pharmacokinet. 2011;50:637–664.
   PubMed Web of Science ®Google Scholar
• Marchand S, Chauzy A, Dahyot-Fizelier C, et al. Microdialysis as a way to measure antibiotics concentration in tissues. Pharmacol Res. 2016;111:201–207.
   PubMed Web of Science ®Google Scholar
• Mouton JW, Theuretzbacher U, Craig WA, et al. Tissue concentrations: do we ever learn?. J Antimicrob Chemother. 2008;61:235–237.
   PubMed Web of Science ®Google Scholar
• Hollenstein UM, Brunner M, Schmid R, et al. Soft tissue concentrations of ciprofloxacin in obese and lean subjects following weight-adjusted dosing. Int J Obes Relat Metab Disord. 2001;25:354–358.
   PubMed Web of Science ®Google Scholar
• Barbour A, Schmidt S, Rout WR, et al. Soft tissue penetration of cefuroxime determined by clinical microdialysis in morbidly obese patients undergoing abdominal surgery. Int J Antimicrob Agents. 2009;34:231–235.
   PubMed Web of Science ®Google Scholar
• Zeitlinger MA, Traunmüller F, Abrahim A, et al. A pilot study testing whether concentrations of levofloxacin in interstitial space fluid of soft tissues may serve as a surrogate for predicting its pharmacokinetics in lung. Int J Antimicrob Agents. 2007;29:44–50.
   PubMed Web of Science ®Google Scholar
• Bauer MP, Van De Garde EMW, Van Kasteren MEE, et al. SWAB guideline: Perioperative antibiotic prophylaxis. 2017. Available at: http://www.swab.nl/richtlijnen
   Google Scholar
• Machado M, Marques-Vidal P, Cortez-Pinto H. Hepatic histology in obese patients undergoing bariatric surgery. J Hepatol. 2006;45:600–606.
   PubMed Web of Science ®Google Scholar
• Dong D, Peng X, Liu J, et al. Morbid obesity alters both pharmacokinetics and pharmacodynamics of propofol: dosing recommendation for anesthesia induction. Drug Metab Dispos. 2016;44:1579–1583.
   PubMed Web of Science ®Google Scholar
• Diepstraten J, Chidambaran V, Sadhasivam S, et al. An integrated population pharmacokinetic meta-analysis of propofol in morbidly obese and nonobese adults, adolescents, and children. CPT Pharmacometrics Syst Pharmacol. 2013;2:e73.
   PubMedGoogle Scholar
• Ingrande J, Brodsky JB, Lemmens HJM. Lean body weight scalar for the anesthetic induction dose of propofol in morbidly obese subjects. Anesth Analg. 2011;113:57–62.
   PubMed Web of Science ®Google Scholar
• Yoshinari K, Takagi S, Yoshimasa T, et al. Hepatic CYP3A expression is attenuated in obese mice fed a high-fat diet. Pharm Res. 2006;23:1188–1200.
   PubMed Web of Science ®Google Scholar
• Kolwankar D, Vuppalanchi R, Ethell B, et al. Association between nonalcoholic hepatic steatosis and hepatic cytochrome P-450 3A activity. Clin Gastroenterol Hepatol. 2007;5:388–393.
   PubMed Web of Science ®Google Scholar
• Ghose R, Omoluabi O, Gandhi A, et al. Role of high-fat diet in regulation of gene expression of drug metabolizing enzymes and transporters. Life Sci. 2011;89:57–64.
   PubMed Web of Science ®Google Scholar
• Woolsey SJ, Mansell SE, Kim RB, et al. CYP3A activity and expression in nonalcoholic fatty liver disease. Drug Metab Dispos. 2015;43:1484–1490.
   PubMed Web of Science ®Google Scholar
• Banerjee M, Robbins D, Chen T. Targeting xenobiotic receptors PXR and CAR in human diseases. Drug Discov Today. 2015;20:618–628.
   PubMed Web of Science ®Google Scholar
• Brill MJ, Van Rongen A, Van Dongen EP, et al. The pharmacokinetics of the CYP3A substrate midazolam in morbidly obese patients before and one year after bariatric surgery. Pharm Res. 2015;32:3927–3936.
   PubMed Web of Science ®Google Scholar
• Emery MG, Fisher JM, Chien JY, et al. CYP2E1 activity before and after weight loss in morbidly obese subjects with nonalcoholic fatty liver disease. Hepatology. 2003;38:428–435.
   PubMed Web of Science ®Google Scholar
• Caraco Y, Zylber-Katz E, Berry EM, et al. Caffeine pharmacokinetics in obesity and following significant weight reduction. Int J Obes Relat Metab Disord. 1995;19:234–239.
   PubMed Web of Science ®Google Scholar
• Van Rongen A, Vaughns JD, Moorthy GS, et al. Population pharmacokinetics of midazolam and its metabolites in overweight and obese adolescents. Br J Clin Pharmacol. 2015;80:1185–1196.
   PubMed Web of Science ®Google Scholar
• FDA. Food and Drug Administration, Center for Drug Evaluation and Research, Advisory Committee for Pharmaceutical Science and Clinical Pharmacology (ACPS-CP) meeting. March 14, 2012.
   Google Scholar
• Calvier EAM, Krekels EHJ, Välitalo PAJ, et al. Allometric scaling of clearance in paediatric patients: when does the magic of 0.75 fade? . Clin Pharmacokinet. 2017;56:273–285.
   PubMed Web of Science ®Google Scholar
• Vaughns JD, Ziesenitz VC, Williams EF, et al. Use of fentanyl in adolescents with clinically severe obesity undergoing bariatric surgery: a pilot study. Paediatr Drugs. 2017;19:251–257.
   PubMed Web of Science ®Google Scholar
• Lloret-Linares C, Luo H, Rouquette A, et al. The effect of morbid obesity on morphine glucuronidation. Pharmacol Res. 2017;118:64–70.
   PubMed Web of Science ®Google Scholar
• De Hoogd S, Välitalo PAJ, Dahan A, et al. Influence of morbid obesity on the pharmacokinetics of morphine, morphine-3-glucuronide, and morphine-6-glucuronide. Clin Pharmacokinet. 2017;56:1577–1587.
   PubMed Web of Science ®Google Scholar
• Ferslew BC, Johnston CK, Tsakalozou E, et al. Altered morphine glucuronide and bile acid disposition in patients with nonalcoholic steatohepatitis. Clin Pharmacol Ther. 2015;97:419–427.
   PubMed Web of Science ®Google Scholar
• Dzierlenga AL, Clarke JD, Hargraves TL, et al. Mechanistic basis of altered morphine disposition in nonalcoholic steatohepatitis. J Pharmacol Exp Ther. 2015;352:462–470.
   PubMed Web of Science ®Google Scholar
• Van Der Schoor LWE, Verkade HJ, Kuipers F, et al. New insights in the biology of ABC transporters ABCC2 and ABCC3: impact on drug disposition. Expert Opin Drug Metab Toxicol. 2015;11:273–293.
   PubMed Web of Science ®Google Scholar
• Fisher CD, Lickteig AJ, Augustine LM, et al. Experimental non-alcoholic fatty liver disease results in decreased hepatic uptake transporter expression and function in rats. Eur J Pharmacol. 2009;613:119–127.
   PubMed Web of Science ®Google Scholar
• Ali I, Slizgi JR, Kaullen JD, et al. Transporter-mediated alterations in patients with NASH increase systemic and hepatic exposure to an OATP and MRP2 substrate. Clin Pharmacol Ther. 2017. DOI:10.1002/cpt.997
   PubMed Web of Science ®Google Scholar
• Chagnac A, Herman M, Zingerman B, et al. Obesity-induced glomerular hyperfiltration: its involvement in the pathogenesis of tubular sodium reabsorption. Nephrol Dial Transplant. 2008;23:3946–3952.
   PubMed Web of Science ®Google Scholar
• Levey AS, Inker LA. Assessment of glomerular filtration rate in health and disease: a state of the art review. Clin Pharmacol Ther. 2017;102:405–419.
   PubMed Web of Science ®Google Scholar
• Pai MP. Estimating the glomerular filtration rate in obese adult patients for drug dosing. Adv Chronic Kidney Dis. 2010;17:53–62.
   PubMedGoogle Scholar
• Demirovic JA, Pai AB, Pai MP. Estimation of creatinine clearance in morbidly obese patients. Am J Heal Syst Pharm. 2009;66:642–648.
   PubMed Web of Science ®Google Scholar
• Lim WH, Lim EM, McDonald S. Lean body mass-adjusted Cockcroft and Gault formula improves the estimation of glomerular filtration rate in subjects with normal-range serum creatinine. Nephrology. 2006;11:250–256.
   PubMed Web of Science ®Google Scholar
• Bauer LA, Edwards WAD, Dellinger EP, et al. Influence of weight on aminoglycoside pharmacokinetics in normal weight and morbidly obese patients. Eur J Clin Pharmacol. 1983;24:643–647.
   PubMed Web of Science ®Google Scholar
• Alobaid AS, Wallis SC, Jarrett P, et al. Effect of obesity on the population pharmacokinetics of fluconazole in critically ill patients. Antimicrob Agents Chemother. 2016;60:6550–6557.
   PubMed Web of Science ®Google Scholar
• Chairat K, Jittamala P, Hanpithakpong W, et al. Population pharmacokinetics of oseltamivir and oseltamivir carboxylate in obese and non-obese volunteers. Br J Clin Pharmacol. 2016;81:1103–1112.
   PubMed Web of Science ®Google Scholar
• Thorne-Humphrey LM, Goralski KB, Slayter KL, et al. Oseltamivir pharmacokinetics in morbid obesity (OPTIMO trial). J Antimicrob Chemother. 2011;66:2083–2091.
   PubMed Web of Science ®Google Scholar
• Jittamala P, Pukrittayakamee S, Tarning J, et al. Pharmacokinetics of orally administered oseltamivir in healthy obese and nonobese Thai subjects. Antimicrob Agents Chemother. 2014;58:1615–1621.
   PubMed Web of Science ®Google Scholar
• Christoff PB, Conti DR, Naylor C, et al. Procainamide disposition in obesity. Drug Intell Clin Pharm. 1983;17:516–522.
   PubMedGoogle Scholar
• Allard S, Kinzig M, Boivin G, et al. Intravenous ciprofloxacin disposition in obesity. Clin Pharmacol Ther. 1993;54:368–373.
   PubMed Web of Science ®Google Scholar
• Bardin C, Nobecourt E, Larger E, et al. Population pharmacokinetics of metformin in obese and non-obese patients with type 2 diabetes mellitus. Eur J Clin Pharmacol. 2012;68:961–968.
   PubMed Web of Science ®Google Scholar
• More VR, Slitt AL. Alteration of hepatic but not renal transporter expression in diet-induced obese mice. Drug Metab Dispos. 2011;39:992–999.
   PubMed Web of Science ®Google Scholar
• Reiss RA, Haas CE, Karki SD, et al. Lithium pharmacokinetics in the obese. Clin Pharmacol Ther. 2015;71:1501–1508.
   Google Scholar
• Huttunen R, Syrjänen J. Obesity and the risk and outcome of infection. Int J Obes. 2013;37:333–340.
   PubMed Web of Science ®Google Scholar
• Varin F, Ducharme J, Theoret Y, et al. Influence of extreme obesity on the body disposition and neuromuscular blocking effect of atracurium. Clin Pharmacol Ther. 1990;48:18–25.
   PubMed Web of Science ®Google Scholar
• Jullian-Desayes I, Revol B, Chareyre E, et al. Impact of concomitant medications on obstructive sleep apnoea. Br J Clin Pharmacol. 2017;83:688–708.
   PubMed Web of Science ®Google Scholar
• Mason M, Cates CJ, Smith I. Effects of opioid, hypnotic and sedating medications on sleep-disordered breathing in adults with obstructive sleep apnoea. Cochrane Database Syst Rev. 2015;7:CD011090.
   PubMed Web of Science ®Google Scholar
• Goulooze SC, Krekels EHJ, Van Dijk M, et al. Towards personalized treatment of pain using a quantitative systems pharmacology approach. Eur J Pharm Sci. 2017;109S:S32–S38.
   PubMedGoogle Scholar
• De Cock RFW, Allegaert K, Schreuder MF, et al. Maturation of the glomerular filtration rate in neonates, as reflected by amikacin clearance. Clin Pharmacokinet. 2012;51:105–117.
   PubMed Web of Science ®Google Scholar
• Smits A, De Cock RFW, Allegaert K, et al. Prospective evaluation of a model-based dosing regimen for amikacin in preterm and term neonates in clinical practice. Antimicrob Agents Chemother. 2015;59:6344–6351.
   PubMed Web of Science ®Google Scholar